company background image
9926 logo

Akeso SEHK:9926 Stock Report

Last Price

HK$64.50

Market Cap

HK$55.8b

7D

-13.3%

1Y

65.2%

Updated

12 Oct, 2024

Data

Company Financials +

9926 Stock Overview

A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.

9926 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Akeso, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Akeso
Historical stock prices
Current Share PriceHK$64.50
52 Week HighHK$77.65
52 Week LowHK$26.45
Beta0.51
11 Month Change14.56%
3 Month Change60.45%
1 Year Change65.17%
33 Year Change43.02%
5 Year Changen/a
Change since IPO165.43%

Recent News & Updates

Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Sep 09
Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Recent updates

Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Sep 09
Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 30
Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24
Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Jun 19
Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

May 31
Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Apr 24
Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Mar 25
We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20
Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Dec 28
Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Nov 16
An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Is Akeso (HKG:9926) Using Too Much Debt?

Oct 02
Is Akeso (HKG:9926) Using Too Much Debt?

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31
The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Jun 26
Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

May 22
There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Apr 11
Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Mar 21
Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Mar 02
An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01
Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Aug 28
Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Shareholder Returns

9926HK BiotechsHK Market
7D-13.3%-10.1%-6.2%
1Y65.2%-4.2%17.6%

Return vs Industry: 9926 exceeded the Hong Kong Biotechs industry which returned -4.2% over the past year.

Return vs Market: 9926 exceeded the Hong Kong Market which returned 17.6% over the past year.

Price Volatility

Is 9926's price volatile compared to industry and market?
9926 volatility
9926 Average Weekly Movement10.0%
Biotechs Industry Average Movement10.4%
Market Average Movement8.7%
10% most volatile stocks in HK Market18.5%
10% least volatile stocks in HK Market4.3%

Stable Share Price: 9926 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 9926's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20122,815Michelle Xiawww.akesobio.com

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.

Akeso, Inc. Fundamentals Summary

How do Akeso's earnings and revenue compare to its market cap?
9926 fundamental statistics
Market capHK$55.85b
Earnings (TTM)-HK$808.61m
Revenue (TTM)HK$2.06b

27.1x

P/S Ratio

-69.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9926 income statement (TTM)
RevenueCN¥1.87b
Cost of RevenueCN¥146.05m
Gross ProfitCN¥1.73b
Other ExpensesCN¥2.46b
Earnings-CN¥735.33m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin92.21%
Net Profit Margin-39.24%
Debt/Equity Ratio64.2%

How did 9926 perform over the long term?

See historical performance and comparison